Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBFB | Q13951 | 1/20 | 0.48 |
| ▸ | PDE2A | O00408 | 8/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TNKS | O95271 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18036035 | 0.84 | PDE2A (0.51) | PDE2APTGES | |
| SCHEMBL18036112 | 0.82 | SIRT6 (0.44) | PDE2APTGESTDP1 | |
| SCHEMBL18035966 | 0.80 | HIF1A (0.44) | PDE2APTGESMCL1HIF1A | |
| SCHEMBL18036014 | 0.79 | RUNX1 (0.45) | PDE2AALPL | |
| SCHEMBL18036137 | 0.78 | PDE2A (0.40) | PDE2AKDM4EALDH1A1POLBGAA | |
| SCHEMBL18036230 | 0.78 | PDE2A (0.42) | PDE2APTGESKDM4EALDH1A1POLB | |
| SCHEMBL18036113 | 0.76 | PDE2A (0.48) | PDE2AKDM4ETDP1L3MBTL1HIF1A | |
| SCHEMBL18036027 | 0.75 | CBFB (0.44) | CBFBKDM4EALDH1A1POLBGAA | |
| SCHEMBL18036045 | 0.74 | NPC1 (0.51) | CBFBPDE2AKDM4EALDH1A1GAA | |
| SCHEMBL18036079 | 0.71 | CBFB (0.49) | CBFBPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264536-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-15 | — | — | US | disclosed |
| EP-3061754-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264536-A1 | HETEROCYCLIC COMPOUND | PDE2A, PDE5A, PDE3A | CBFB 3655/4885PDE2A 1/4885PTGES 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.